NCT07427498 The Role of Priors in Hallucinatory Perception in Parkinson's Disease
| NCT ID | NCT07427498 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | PARKINSON DISEASE (Disorder) |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-04-28 |
| Primary Completion | 2028-04-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2026-04-28 with a primary completion date of 2028-04-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to better understand the mechanisms of hallucinations in patients with Parkinson's disease. The main question it aims to answer is: Do prior expectations increase the rate of false perceptions during a visual stimulus detection task more in Parkinson's disease patients with visual hallucinations compared to those without? Participants will undertake a computer task involving face detection and a battery of neuropsychological tests.
Eligibility Criteria
Inclusion Criteria: * Adults diagnosed with Parkinson's disease (with or without visual hallucinations) or healthy volunteers. * Age 18 - 85 years. * Consent to participate. Exclusion Criteria: * Currently participating in another clinical or therapeutic trial involving the testing of a drug treatment. * Inability to perform cognitive tests due to: Non-psychiatric (somatic) conditions likely to affect cognitive abilities. Peripheral sensory or motor deficits. Acute clinical conditions (e.g., agitation, impaired consciousness). * Diagnosis of dementia. * Individuals covered by Articles L1121-5 to L1121-8 of the French Public Health Code (Code de la Santé Publique), including: Pregnant women, women in labor, or breastfeeding mothers. Individuals deprived of liberty by judicial or administrative decision. Individuals receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 (excluding those covered by Article L. 1121-8). Individuals admitted to a healthcare or social institution for purposes other than research. Minors or adults under legal guardianship or unable to express consent. \- Individuals with a hierarchical relationship to any professional involved in the study. Only for healthy volunteers: \- Personal history of diagnosed neurological disorders. Post-Inclusion Exclusion: \- Participants included in the study but found to have a MoCA score below 24 will be excluded from the study.
Contact & Investigator
Anna Castrioto
PRINCIPAL INVESTIGATOR
University Hospital, Grenoble
Frequently Asked Questions
Who can join the NCT07427498 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying PARKINSON DISEASE (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07427498 currently recruiting?
Yes, NCT07427498 is actively recruiting participants. Contact the research team at acastrioto@chu-grenoble.fr for enrollment information.
Where is the NCT07427498 trial being conducted?
This trial is being conducted at Grenoble, France, La Tronche, France.
Who is sponsoring the NCT07427498 clinical trial?
NCT07427498 is sponsored by University Hospital, Grenoble. The principal investigator is Anna Castrioto at University Hospital, Grenoble. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.